A humanized monoclonal antibody that targets CD19+ B cells becomes the first and only FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.
U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.
Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Colorectal cancer patients face up to 45% higher cardiovascular mortality risk within two years of diagnosis, with Black patients and those under 50 experiencing the greatest danger, according to research presented at ACC.25.
FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.
An anesthesiologist has been apprehended in Hawaii after allegedly assaulting his spouse at a popular hiking location, resulting in the closure of the Nu'uanu Pali State Wayside.
Proposals include licensure for community health workers, expanded provider roles, and Medicaid coverage adjustments to address staffing gaps and access barriers.